Pharsight

Aczone patents expiration

ACZONE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517219 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(10 years from now)

US9161926 ALMIRALL Topical dapsone and dapsone/adaplene compositions and methods for use thereof
Nov, 2033

(10 years from now)

US11273132 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof
Nov, 2033

(10 years from now)

Aczone is owned by Almirall.

Aczone contains Dapsone.

Aczone has a total of 3 drug patents out of which 0 drug patents have expired.

Aczone was authorised for market use on 24 February, 2016.

Aczone is available in gel;topical dosage forms.

Aczone can be used as topical treatment of acne vulgaris.

The generics of Aczone are possible to be released after 18 November, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) Sep 10, 2022

Drugs and Companies using DAPSONE ingredient

Market Authorisation Date: 24 February, 2016

Treatment: Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

How can I launch a generic of ACZONE before it's drug patent expiration?
More Information on Dosage

ACZONE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic